Uncertainty and 'technological horizon' in qualitative interviews about HIV treatment by Davis, Mark et al.
www.ssoar.info
Uncertainty and 'technological horizon' in
qualitative interviews about HIV treatment
Davis, Mark; Frankis, Jamie; Flowers, Paul
Postprint / Postprint
Zeitschriftenartikel / journal article
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
www.peerproject.eu
Empfohlene Zitierung / Suggested Citation:
Davis, M., Frankis, J., & Flowers, P. (2006). Uncertainty and 'technological horizon' in qualitative interviews about HIV
treatment. Health, 10(3), 323-344. https://doi.org/10.1177/1363459306064489
Nutzungsbedingungen:
Dieser Text wird unter dem "PEER Licence Agreement zur
Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden
Sie hier: http://www.peerproject.eu Gewährt wird ein nicht
exklusives, nicht übertragbares, persönliches und beschränktes
Recht auf Nutzung dieses Dokuments. Dieses Dokument
ist ausschließlich für den persönlichen, nicht-kommerziellen
Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments
müssen alle Urheberrechtshinweise und sonstigen Hinweise
auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses
Dokument nicht in irgendeiner Weise abändern, noch dürfen
Sie dieses Dokument für öffentliche oder kommerzielle Zwecke
vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder
anderweitig nutzen.
Mit der Verwendung dieses Dokuments erkennen Sie die
Nutzungsbedingungen an.
Terms of use:
This document is made available under the "PEER Licence
Agreement ". For more Information regarding the PEER-project
see: http://www.peerproject.eu This document is solely intended
for your personal, non-commercial use.All of the copies of
this documents must retain all copyright information and other
information regarding legal protection. You are not allowed to alter
this document in any way, to copy it for public or commercial
purposes, to exhibit the document in public, to perform, distribute
or otherwise use the document in public.
By using this particular document, you accept the above-stated
conditions of use.
Diese Version ist zitierbar unter / This version is citable under:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-226008
Uncertainty and
‘technological horizon’ in
qualitative interviews
about HIV treatment
Mark Davis, Jamie Frankis & Paul Flowers
University of East London & Glasgow Caledonian University, UK
ABSTRACT Highly Active Anti-Retroviral Treatment (HAART) has
reduced death and morbidity among people with HIV. However, HAART is
not always effective, can produce serious side-effects and implies uncertainty
for patients. To address HAART-related uncertainty, 20 qualitative interviews
were conducted with gay men with HIV in Glasgow and London. The inter-
viewees were purposively selected to reflect diversity in terms of year of diag-
nosis, experiences of illness and treatment-related side-effects. The interviews
were analysed using the constant comparison method to derive themes.
Among those using HAART, analysis identified themes of ‘good health’,
‘illness’ and ‘loss of confidence’. Uncertainty was managed through a
discourse of ‘technological horizon’ that combined the ongoing innovations
of HAART and biographical time. These themes are discussed in terms of
the implications for HIV care. In particular, technological horizon provides
a basis for the management of uncertainty in the prescribing relationship
between patient and clinician.
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Introduction
This article employs qualitative methodology to address treatment-related
uncertainties in the lived experience of gay men with HIV. Highly Active
Anti-Retroviral Treatment (HAART) was introduced in the mid-1990s in
the affluent West, leading to improved life expectations (Health Protection
Agency, 2004). For people with HIV and their carers, effective HIV treat-
ment has been linked with dramatic changes in lived experience and in
clinical practice (Green and Smith, 2004; Rosengarten et al., 2004). Central
to these adjustments are the uncertainties of the ‘post-HAART’ situation.
Side-effects, the development of drug resistance and treatment intolerance
can undermine the long-term effectiveness of HAART (NAM, 2003).
The 1996 Vancouver AIDS Conference is generally taken as the date
when the epidemic began to change for the better (Holzemer, 1997). At
this conference, evidence was provided that combinations of anti-HIV
drugs effectively reduced viral activity, protecting or restoring the immune
systems of people with HIV. Subsequently, the advent of HAART has come
to be represented as a definite medical watershed in the history of the
epidemic. Accordingly, the situation is variously constructed as post-
HAART,1 post-AIDS (Dowsett, 1998) or as ‘living after crisis’ (Rofes,
1998). HIV infection is now referred to as a chronic manageable infection
(Siegel and Lekas, 2002), while public policy for prevention and treatment
has become normalized (Rosenbrock et al., 2000). However, a review for
the British HIV Association noted that psychological morbidity for people
with HIV was associated with ongoing uncertainty about HAART (Green
and Smith, 2004). In addition, for people with HIV from Africa and living
in the UK, uncertainties about using HAART were sometimes displaced
by concerns over right of abode and access to treatment (Flowers et al.,
2006). Uncertain citizenship and implied lack of access to HAART over-
shadowed the technical uncertainties of HAART.
Much research about the post-HAART situation has adopted a chronic
illness model (Green and Smith, 2004). Such research has focused on the
difficulties of the post-HAART situation and the support needs of people
with HIV (Kalichman et al., 1998; Bogart et al., 2000). This research has
elaborated on the general themes of hope and uncertainty, often with the
aim of establishing frameworks for psychosocial support for the daily
management of pill taking, side-effects and mental health. For example,
researchers have explored the impact of HAART side-effects on people
with HIV. In particular, lipodystrophy (changes in appearance related to
loss of body fat) has been linked with difficulties in sexual practice, treat-
ment adherence and well-being (Dukers et al., 2001; Duran et al., 2001;
Oette et al., 2002; Power et al., 2003). Researchers have also used quali-
tative methodologies to explore the lived experience of the post-HAART
situation. A central concept has been ‘revival discourse’ used by people
with HIV to engage with expanding life options, coupled with uncertainty
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about the long-term effects of treatment (Brashers et al., 1999; Trainor and
Ezer, 2000). Developing this uncertainty thesis, research has mapped out
the cognitive coping strategies of gay men with HIV infection and identi-
fied how they valued autonomy and control, both of which provided strat-
egies for deconstructing life with HIV, preparing the self for uncertainty
and reducing stigma (Siegel and Schrimshaw, 2000).
Researchers have also investigated the challenge of uncertainty for
clinical practice. In general, the uncertainties of HAART are regarded as
a problem for the development of evidence-based prescribing practice. For
example, a systematic review attempted to deal with uncertainty and
decisions about commencing HAART (Wood et al., 2005). UK best practice
guidance also refers to the incompleteness of the evidence base for clinical
practice (http://www.bhiva.org/guidelines/2005/HIV/HIV05frameset.html,
1 December 2005). Uncertainty arises because clinical trials demonstrate
the efficacy of particular treatments, but they do not provide data for long-
term, routine clinical practice, such as for patients who change their treat-
ments because of side-effects and intolerance. Partly as a result, researchers
have explored the dilemmas faced by HIV clinicians themselves (Gerbert
et al., 2004; Rosengarten et al., 2004; Williams et al., 2004). Uncertainties
in treatment outcomes can be reflected in self-reported stress and anxiety
among clinicians (Williams et al., 2004). Gerbert et al. (2000) advocate for
‘relationship-centred HIV clinical care’ as a way of managing treatment
uncertainty, both for the patient and the clinician.
However, much of the research conducted since the advent of effective
treatment is not reflexive with its own assumptions about the post-HAART
situation for people with HIV, although there are some notable exceptions
from the cultural studies of medicine and the body using post-structural
theory. Writing in the period before HAART and drawing on Foucault,
Heaphy (1996) noted how HIV medical technologies created new options
for people with HIV along with additional forms of self-surveillance.
Working in the cultural studies of science and technology, others have
developed this Foucauldian theme for the post-HAART situation. Race
has explored the new forms of surveillance inspired by the capacities of
HAART, identity and the new forms of social relations in clinical care
(Race, 2001a, 2001b). Persson (2004, 2005) has addressed how the side-
effects of HAART are implicated in a reconfigured body with HIV and
how gay men with HIV resist and rework the meanings of changed body
appearance. Rosengarten (2004) has explored the consumer politics in the
social marketing of HIV treatment. Stephenson (2003) argues that the
reflexive practices associated with HIV treatment are also forms of self-
subjection. Such self-subjection is revealed in psycho-medical discourse
about the individual and their well-being (Holt and Stephenson, 2006).
Perspectives such as these imply that the chronic disease/uncertainty
research of the post-HAART situation relies on a deficit model where
people with HIV are seen to lack the skills needed to cope with their life
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with treatment (Adam et al., 2003). This deficit approach also reinforces a
system that divides the knowledge and labour of caring so that professionals
are seen to apply expertise to patients in need. This kind of arrangement
sits at odds with current moves in HIV clinical practice in particular and
the ‘expert patient model’ approach for chronic illness in general (DOH,
2001). A related problem of the deficit model is that it focuses on the
training and development needs of clinicians, overlooking and devaluing
the contribution of patients to making HAART work (Persson, 2004;
Rosengarten, 2004). Such research also fails to engage with contribution of
the treatment advocacy movement to patient–doctor relations and the
practice of HIV treatment (Epstein, 1996; Race, 2001b).
Critical perspectives about the post-HAART situation also lead into
questions about the view that uncertainty is always negative. In much of
the research and intervention that supports care for people with HIV, uncer-
tainty is seen as something that threatens people and that has to be mini-
mized or compensated through emotional support. In this view, uncertainty
is also seen as the opposite of the hope that is embedded in the promise
of biomedicine. However, uncertainty may not be singular and disabling
for the individual. Moreover, it may not be the antonym of hope. Working
in the area of political theory, O’Malley (2000) has identified the positive
value of uncertainty for individuals. In this view, uncertainty is a more
neutral resource for active social agents. Lupton (1999) has discussed how
‘edgework’ in the face of danger is used to find a way of proving oneself,
securing social status, achieving maturational milestones and presenting
identity. Given that uncertainty is not always singular and detracting, we
are left with a question about why research about the lived experience of
the post-HAART situation constructs uncertainty as negative and against
hope. One possible reason is that treatment uncertainty threatens not only
the individual but also the capacities of biomedicine. The chronic illness
research often makes the point that uncertainty may jeopardize the willing-
ness of individual patients to continue to take HAART properly, therefore
leading to the risk of poor treatment and the development of drug-resist-
ant forms of HIV (see Lee et al., 2002). A related fear may be that patients
may question clinical expertise when uncertainties become overwhelming.
It appears therefore that the uncertainty thesis is not only relevant to the
lived experience of individuals, but also to the governance and status of
biomedicine in the area of HIV and beyond.
The sociology of expectations provides another way of developing
research about HAART-related uncertainties. Outside the area of HIV,
researchers have begun to map out the sociological aspects of expectations
connected with technologies, including health technologies (Webster, 2002;
Brown and Michael, 2003). This research foregrounds the social aspects of
technological innovation, the related implications of uncertainty and the
expectations of technology consumers. Prior to the advent of effective HIV
treatment, Macintyre (1999) interviewed long-term survivors about their
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experiences. One finding was that changes in the prognostic practices of
HIV medicine linked to accumulating data and evolving knowledge about
HIV sometimes undermined the hopeful expectations of people with HIV.
Similar perspectives have emerged in research in the post-HAART situ-
ation, where limited clinical prognoses clash with both personal expec-
tations and post-HAART discourse about the effectiveness of HIV
treatment (Davis, 2005). In addition, research suggests that not all people
with HIV deal with treatment-related uncertainties in the same manner,
therefore questioning the totality and universality of treatment expec-
tations (Davis et al., 2002). Exploring personal engagements with HAART
and uncertainty, Ezzy (2000) identified several different narratives
employed by people with HIV: ‘linear restitutive’; ‘linear chaotic’; and ‘poly-
phonic’. Ezzy argued that linear restitutive and chaotic narratives were
future oriented, entwined with the management of uncertainty and tied to
the achievements of biomedicine in treating HIV infection, but respectively
hopeful or pessimistic about the life course. Polyphonic narratives were
present oriented, less embedded in a sense of linear, biographical time
dependent on HIV treatment innovation and therefore less subject to
uncertainty. Ezzy’s work therefore points out the diversity among people
with HIV in connection with HAART and uncertainty about the life course.
There is a need to develop critical research about the interconnections
between HIV treatment innovation, life expectations and uncertainty.
This article therefore makes several new connections in research about
the post-HAART situation with reference to the reflexive treatment prac-
tices of people with HIV and the critical perspectives of theoretical research
about HIV treatment and biomedical technologies in general. In particu-
lar, this article uses a qualitative interview methodology to question: the
deficit model of the chronic disease approach to research and intervention
in the post-HAART situation; a categorically negative view of treatment-
related uncertainties; the ideological properties of the hope invested in
treatment innovation; and the interplay of uncertainty, expectations and
treatment innovation.
Methods
Background
This research is based on 20 qualitative interviews with gay men with HIV,
conducted for the ‘Transitions in HIV treatment’ project, funded as part
of the ESRC Innovative Health Technologies Programme (http://www.
york.ac.uk/res/iht/). This project had several components, including: 68
interviews with people with HIV living in Glasgow and London (including
gay men, injecting drug users and people from Africa residing in the UK);
16 interviews with carers and treatment advocates; a literature review of
the way risk identity is operationalized in the medical science underpin-
ning HIV treatment innovation; and a textual analysis of social marketing
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of HIV treatment. One of the central aims of the project was to provide
an account of the impact of effective HIV treatment on HIV positive
people’s experience of the disease, their changed understanding of their
bodies in relation to HIV medical technologies and the assimilation of this
knowledge into their identities. Another aim was to explore two different
social and clinical settings (Glasgow and London), with a view to develop-
ing an account of transition that would be relevant beyond London, where
most clinical research is done in the UK. Two areas of the analysis have
been reported: the perspectives of people from Africa (Flowers et al., 2006)
and HIV clinicians (Rosengarten et al., 2004). This article therefore
addresses the lived experience of gay and bisexual men living in Glasgow
and London. The qualitative interview research adopted an iterative, induc-
tive methodology (Strauss and Corbin, 1998).
Sampling
Volunteers for the interviews were recruited from HIV outpatient clinics
in London (n = 10) and in Glasgow recruited both through clinics and a
local HIV charity (n = 10). The samples were broadly representative of the
gay male clinic populations (see Table 1). The volunteers were aged
between 28 and 55. The London sample reflected the ethnic diversity of
that city. Two interviewees had an African background and one had an
Asian background. Nine of the interviewees were diagnosed prior to, or
during, the HAART watershed in 1996. Four participants had never taken
HAART. Eleven interviewees were diagnosed with HIV infection after
1996.
The interviews
The interviews were conducted between July 2001 and June 2002. The same
topic guide was used in Glasgow and London. The interviewees were asked
to talk about their experiences of using HAART, with a focus on lived
experience before and after the introduction of HAART in 1996. Areas for
discussion included: current HAART regimen and dosing difficulties (in
particular, cessation of treatment due to intolerance or side-effects);
previous HAART regimen(s) (if applicable); participation in clinical trials
(if applicable); understanding of drug resistance, CD4 count and viral load
(with reference to assessment, monitoring and impact on prognosis), treat-
ment side-effects and risk management strategies (regimen change, treat-
ment cessation, treatment holidays); strategies for managing the impact of
treatment on everyday life (work, socializing, sexual practice); sources
of practical and emotional support; expectations for the future; assessment
of the ‘risks’ of living with HAART (health, social, employment, relation-
ships, sexual practice, disclosure, reinfection); understandings of the body
with HIV; and use of HIV services. If not using HAART, interviewees were
asked to talk about their expectations about using treatment, decisions to
take it and understandings of side-effects and drug resistance.
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Ethics
Interviewees were asked to provide written or e-mail consent once they
had read an information sheet that described the study purpose and how
their interview would be anonymized and used in the research. Ethical
committee approval was granted from Glasgow Caledonian University
Psychology Department, Glasgow Royal Infirmary University NHS Trust
and UCL Hospitals Research Ethics Committee. During the interviews it
was made clear to participants that they were under no obligation to answer
particular questions and that at any time they were free to terminate the
interview and withdraw from the study. Interviewee transcripts are identi-
fied by a pseudonym, location (Glasgow or London), age, ethnicity and year
of diagnosis.
Analysis
Using constant comparison, themes were generated pertaining to the
experience of considering or using HAART (Strauss and Corbin, 1998).
The analysis of Glasgow and London interviews was combined
because these did not suggest major differences between the locations in
accounts of the experience of using HAART. Themes were justified with
analytical memoranda. Analytical bias was addressed through transparent
Davis et al.: Uncertainty and ‘Technological Horizon’ in HIV Treatment
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Table 1 Age, year of HIV diagnosis and year commenced HAART for interviewees in
Glasgow and London
Location Age Year of HIV Year commenced
diagnosis HAART
Alan Glasgow 34 2001 None
Ben Glasgow 40 1997 HAART
Colin Glasgow 28 2000 HAART
David Glasgow 55 1998 None
Edward Glasgow 32 2001 HAART
Frank Glasgow 43 1998 HAART
George Glasgow 40 1996 HAART
Henry Glasgow 38 1995 HAART
Ian Glasgow 37 1992 HAART
James Glasgow 32 1999 None
Kevin London 40 1994 HAART
Liam London 55 1986 HAART
Michael London 37 1998 HAART
Neil London 52 1986 HAART
Oscar London 48 1984 HAART
Perry London 47 1992 HAART
Russell London 33 1998 HAART
Stanley London 42 1985 HAART
Timothy London 30 1997 None
Tony London 28 2000 HAART
Note: Names are pseudonyms.
documentation (NVIVO), justifying the viability of themes with reference
to negative cases and team-based interpretive analysis (Popay and Williams,
1997; Silverman, 2000). Data presented in the following are identified with
pseudonyms, location (London or Glasgow), age, year of HIV diagnosis and
whether or not currently using HAART.
Findings
The findings are discussed in three parts. First, we provide an overview of
how the interviewees accounted for aspects of the post-HAART situation
including: general responses; using HIV clinics; the link between adherence
and uncertainty; and social stigma. Second, we identify the several ‘modes’
of accounting related to different experiences of using HAART, illness and
side-effects and personal engagements with uncertainty. Finally, we discuss
‘technological horizon’ as the main method used by patients to negotiate
the uncertainties of the post-HAART situation.
The post-HAART situation for gay men with HIV
Consistent with recent published accounts, the interviewees referred to
improved life expectations because of HAART (Trainor and Ezer, 2000;
Lee et al., 2002). For example, this interviewee, Kevin, reflects on his experi-
ence of HIV diagnosis prior to the introduction of HAART:
when I was first diagnosed, like before, people with HIV, it was like, you didn’t
have a long life, you couldn’t think that you would be alive in 10 years’ time.
Whereas now with everything that’s happened . . . whereas before I don’t think
there was the option so, yes, it’s not the end of the world. It’s a hurdle. You’ve
got to look at intelligently and think yes, I can continue to have a great life.
(Kevin, London, 40, 1994, HAART)
Kevin acknowledges that the process of taking up HAART is not seamless,
but that problems need to be set against the increase in life prospects. But
it also seemed that life expectations were somewhat limited because of the
uncertainties entailed in medical prognosis:
if I said to my doctor: ‘What are my chances over the next five years’, he would
still probably say: ‘Well they are reasonable for three years but after that can’t
really say.’ And that’s always been the same, the whole way through. (Neil,
London, 52, 1986, HAART)
Neil indicates that formal prognosis has remained the same pre- and post-
HAART. While the improved life prospects attributed to HAART are
recognized, medicine itself is more circumspect. There is a difference then
between how HAART is popularly constructed and what medical science
will allow. Uncertainty is the important aspect of these different prognos-
tic calculations. In the accounts of gay men with HIV, uncertainty is
managed by drawing out the implied opportunity of HAART and not
dwelling on the negative. In medical prognosis, uncertainty is managed as
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a technical exercise of estimation based on the observed life chances of
clinical cohorts. The challenge for gay men with HIV is dealing with both
kinds of engagements with uncertainty. Perhaps as a result, interviewees
had difficulties planning for the future:
I have to turn my life around really because one thing it does do which is I think
very sad is you don’t make any plans for the future. No long-term plans. Now
you know, even at my age I’m sure if there is nothing wrong I would still want
to buy a house, get a mortgage, do a bit of work over, do you know what I am
saying but there is nothing, you are just existing. (Oscar, London, 48, 1984,
HAART)
This example draws attention to the liminal or in-between quality of the
post-HAART experience. When using HAART, imminent death recedes,
but a future life is difficult to entertain.
In contrast with recent accounts of the post-HAART experience of
uncertainty among people with HIV, the accounts in this study were marked
by heterogeneity (Lee et al., 2002). Interviewees referred to various forms
of engagement with aspects of HAART such as interpretations of blood
tests used to monitor treatment, methods of self-care and their relationship
with the prescribing clinician. For example, some interviewees constructed
themselves as proactive, interested in influencing their doctors and in
constructing effective communication:
R: I went on the drugs because I decided beforehand that if my viral load went
over 100,000 or if my T-cell count went under 200 then it would’ve been time
to start talking with my doctor about going on drugs or going on some regime.
I: What do you attribute your ability to be informed about treatments and being
able to manage your own care like that?
R: I’m not sure really. It’s just that, you know, when I found out I thought ‘oh
well, all right, we’ve got to deal with this’ and the only way I can deal with
it is by getting more knowledge about it. (Russell, London, 33, 1998, HAART)
However, other interviewees were less interested in actively shaping the
clinical encounter, preferring to reduce their health care to a routine reliant
on the professional expertise of the doctor:
I mean obviously I don’t sort of read up about everything. It’s things like you
know I was reading in the Aids Update this morning that TB is on the rise. So
things like that I find more interesting, than medication. I just leave that to [HIV
Clinician]. He’ll choose what combination he wants me on. I’m quite happy as
I say I trust [HIV Clinician] to not kill me. [Laughs] (Ian, Glasgow, 37, 1992,
HAART)
The contrast between these forms of engagement with the practice of HIV
prescribing is important for conceptualizing HIV care. The accounts suggest
that HIV care needs to be able to accommodate both a traditional division
of expertise between the clinician and the patient and the participatory
‘expert patient’ model.
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Previous research has also suggested that the rigours and uncertainties
of HAART may undermine treatment compliance (Lee et al., 2002). In
general, the interviewees in our study did not report current difficulties with
taking their drugs nor was dosing connected in the accounts with uncer-
tainty. Discussion of adherence reflected the need to build pill taking into
everyday life and find support to do so:
Well I was put into triple therapy immediately, quite heavy and I had to take
lots of other stuff as well, massive doses of antibiotics for about two years, all
sorts of extra . . . all sorts of extra things, you know, like prophylactics and stuff
like that and at first it was quite hard but again the people at the clinic were
very good, very supportive, and I was quite impressed . . . there were times when
I was taking over 30 tablets and some of them had to be taken on an empty
stomach, some of them had to be taken with food, and it was a very, very oppres-
sive regime. This one is less . . . there’s still a lot of tablets but it’s a lot less and
there’s only one of them now that I take first thing in the morning that requires
an empty stomach. The other ones I can eat, not eat, drink. (Ben, Glasgow, 40,
1997, HAART)
Some aspects of the post-HAART situation for gay men resemble pre-
HAART. As established in other recent research, the interviewees
expressed enduring concerns about HIV-related stigma in health care, in
the gay community and in sexual practice (Dodds et al., 2004). In particu-
lar, the interviewees were concerned about changes in appearance that
might signal HIV status, disclosing HIV serostatus to work colleagues,
family members and to sexual partners. An additional focus for inter-
viewees was the risk of HIV transmission to sexual partners. Despite effec-
tive treatments therefore, gay men with HIV still experience significant
problems of identity and social interaction connected with their serostatus.
Different modes of the post-HAART experience
A key part of the research involved asking interviewees what they thought
and felt about their experience of considering or using HAART. This
achieved a deeper, heterogeneous analysis of engagements with uncertainty.
In an effort to analyse the complexity of these accounts, we grouped them
into different ‘modes’ of the post-HAART experience. The first mode
comprises the ‘before treatment’ accounts of those interviewees who had
not yet used HAART. The remaining modes comprise ‘after treatment’
accounts: ‘good health’; ‘post-illness’; and ‘loss of confidence’. We do not
assert that these ‘after treatment’ modes are fixed in time or mutually exclus-
ive. Nor do we have a sense of the numbers of patients for whom each mode
might be relevant, a point we will return to in the discussion in connection
with the evaluation and monitoring of HAART in the clinic. But, the differ-
ent modes attest to the diversity of the post-HAART situation for gay men
with HIV and the emerging challenges for HIV health care.
In the ‘before treatment’ mode, interviewees who had not yet taken
HAART had a general understanding of it and some concerns. They
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described treatment by referring to what they had gleaned from treatment
information sources, carers and gay men in their social networks using it.
For example, interviewees admitted their lack of knowledge and involve-
ment with treatment: ‘I don’t know an awful lot about it. I mean I’ve not
really got involved in all that sort of side of things because at the moment
I’m healthy, I see myself as healthy’ (James, Glasgow, 32, 1999, never used
HAART). From a position of healthiness, James constructs HAART as
distant and less relevant.
Interviewees in the ‘before treatment’ mode had an idealized understand-
ing of how HAART works:
Well, from what I understand about them, it’s now different courses for people
depending on what kind of strain you’ve got and how advanced it is or how fast
it’s coming on you . . . what I understand it can be as little as two tablets to be
taken each day. And as you react to the tablets they’ll change them and change
the doses until they’ve got the one that suits you . . . I just take it when it’s my
turn to need them then I’ll just obviously leave that to the professionals. (Alan,
Glasgow, 34, 2001, never used HAART)
In this example, Alan brings together an idealized vision of HAART and
a traditional notion of the doctor/patient relationship. The account reflects
awareness that HAART is tailored to personal circumstances through the
guidance of experts. It is a vision of HAART that invests trust in the tech-
nology and HIV prescribing. Interviewees in the pre-treatment mode were
also aware that using HAART was not easy: ‘I’m not worried, but I think
the fact that you have to keep to a regime the rest of your life is kind of
daunting’ (David, Glasgow, 55, 1998, never used HAART). In the pre-
treatment mode of accounting, HAART emerges as a technologized
process and a significant consideration, but not overly problematic.
The other identified modes of the HAART experience were constructed
by interviewees using HAART. The good health accounts were made by
interviewees who found HAART unproblematic. These interviewees
reported no serious illness related to either HIV or side-effects associated
with treatment:
I usually feel quite well because, although there’s been a lot of permanent
damage done, and some significant changes in my appearance and body, the
results have been fantastic . . . there’s been a couple of hitches on the way, but
it’s mainly been consistently good, so the results are fine. (Ben, Glasgow, 40, 1997,
HAART)
. . . had no real problems, skin problems occasionally, diarrhoea, occasional
headaches . . . but otherwise the therapy’s been brilliant. (Kevin, London, 40,
1994, HAART)
In these accounts, HAART side-effects are minor, temporary and manage-
able. HAART itself is seen as reliable and effective. Uncertainties do not
intrude. However, in some cases, the interviewees also preferred to not
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reflect on HAART-related uncertainties too much, adopting a stoic
approach:
Half the battle I think is in your mind too. I mean it’s a terminal disease. It’s
gonna get me eventually . . . but you can’t linger on it. I feel good today. You’re
gonna live good today. (Colin, Glasgow, 28, 2000, HAART)
it’s not something I want to forget, but it’s not something I want in the forefront
all the time . . . I don’t dwell on it. I think there was a time where obviously I
dwelt on it. But now it’s like fine, just get on with it . . . I think that really you
should talk to people . . . different types of terminal illnesses so that you see
other things, and learn other things and it’s not just sort of HIV. (Kevin, London,
40, 1994, HAART)
These latter examples of accounts of good health indicate the presence of
some uncertainty about the future. But this uncertainty is managed by not
focusing on HIV or treatment prospects and by relativizing the experience
with that of other chronic illness. A traditional interpretation of such cogni-
tive strategies might be to think about the function of social comparison or
denial. However, these ways of accounting may also reflect the active
management of uncertainty.
A further contrasting set of accounts was derived from interviews with
gay men who had experienced serious illness and side-effects. These events
occurred prior to, or in parallel with, the introduction of HAART in the
mid to late 1990s. They were related to HAART side-effects and intoler-
ance. These accounts expressed the strain of the stamina required to use
HAART and emotional fragility:
it’s six of one or half a dozen of the other. It is better in one area but there is a
downside to it and side-effects and various other things like muscle wastage and
cramps and falling. You know my legs gave way and, yes, there is an up side. But
there is also a down side. It’s not smooth sailing believe you me. It isn’t. But I
feel if I didn’t go on treatment it would have been downhill much faster. At least
this way there is sort of like – I suppose it’s like a leaking tap. You put a tourni-
quet around it and you are hoping it won’t burst out, but the tourniquet will
prevent the water from gushing out for as long as you can. (Oscar, London, 48,
1984, HAART)
Oscar’s account provides a different picture of the HAART experience. In
place of the unreserved endorsement of HIV treatment, there is ambiv-
alence about the experience and a sense of the strain of managing mind
and body in the long term. The ‘leaking tap’ metaphor works to underline
the temporary quality of HAART and its meaning in these accounts of
something makeshift until such time as a better solution can be found.
Another set of accounts suggested a ‘loss of confidence’ in using HAART.
Interviewees using this mode of accounting referred to experiences with
serious illness and side-effects and expressed distress. In this mode,
HAART and the related caring was seen to be failing:
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other things have happened and so I have a huge gum disease that can be, but
maybe it is not linked to HIV . . . I’ve lost many, many teeth, and I’m losing them
all. It’s just a matter of time and now I don’t have confidence any more . . .
doctors are always in a hurry. They’re always in a hurry. I never arrived late for
an appointment. Many times even if the patient before me didn’t come they’re
in a hurry . . . you know they never have time for you. (Perry, London, 47, 1992,
HAART)
In this example, Perry expresses a loss of faith in both treatment and HIV
care. Questions about the effectiveness of HAART led interviewees to chal-
lenge the idea that HAART was treatment as such or that its effectiveness
could be sustained in the long term:
To call it a treatment is a real misnomer because what happens is the press gets
hold of it and they start writing articles about new treatments and they’re not
treatments at all because treatment I think infers that it’s a cure [and that] HIV
has now become a manageable thing. HIV therapies aren’t either of those things.
At the moment it’s a short stop thing that in most cases has awful side-effects,
some in the short term and some in the long term that people don’t even know
yet . . . People were saying these are fine. You might get diarrhoea. A bit of
nausea or whatever or something, but they’re all manageable, there’s nothing
life-threatening and of course it’s not the case. The fact that kidneys have got
holes in them and leak because of DDI. I was prescribed DDI and no-one knew
such a thing would happen . . . I don’t think either it’s a treatment or it’s a
management of HIV. A short stop-gap to try and give you a bit of extra time in
the hope that newer and better drugs will come along that will be able to treat
it or manage it long term or maybe have a cure. (Stanley, London, 42, 1985,
HAART)
I’m like 10 years down the line and you know . . . my viral load is undetectable,
and it has been for a couple of years now and I just think you know the bubble’s
going to burst at some point. I suppose it’s quite, is it pessimistic? You know, to
think that way but you think, how long can you go? (Ian, Glasgow, 37, 1992,
HAART)
These ‘loss of confidence’ accounts contrast with the other modes of
accounting. In place of a reified notion of HAART we see more fragile
accounts incorporating the distress related to increasingly uncertain futures.
From their points of view, HIV care was insufficient and the public repre-
sentation of HAART was misleading.
Managing uncertainty and the value of technological horizon
As we have discussed, the post-HAART situation implies the challenge of
combining the use of treatment, life expectations and uncertainty. Uncer-
tainty is met by forming self-management strategies in connection with the
sense of unfolding technology and therefore unfolding futures. With refer-
ence to the innovative health technologies and sociology of expectations
literature, we conceptualize HIV treatment reflexivity as ‘technological
horizon’ (Webster, 2002; Brown and Michael, 2003). Technological horizon
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is comprised of the unfolding quality of the changes and developments that
underpin HAART, a sense of the life course interconnected with HAART
and the uncertainties entailed in using it. HAART itself was seen as more
than a definite object or practice. The pills themselves, blood tests and
clinical routines were crucial to the management of effective treatment and
central to experience. But the implications of these elements of HAART
were interpreted in terms of the idea of the ongoing innovation of HAART
and therefore the implications for biographical time. Along with the day-
to-day tasks of drug dosing and regular attendance at clinics for blood tests,
patients were focused on optimizing the positive and avoiding the negative
aspects of HAART through this concept of technological horizon. The
interviewees did not necessarily see themselves as passive in connection
with uncertainty. In addition, the everyday, personalized strategies of uncer-
tainty management, framed by technological horizon, contrast with the
more general, ideological hope that sustains biomedical enterprise. Techno-
logical horizon was relevant to interviewees with differing engagements
with HAART, illness experiences and side-effects. Interviewees referred to
preserving treatment for later, carefully choosing treatment options and
treatment changes and looking forward to technical advances in HAART.
The following extracts demonstrate how interviewees considered that
HIV treatment was in part a function of improving technologies and time:
my actual medical care the whole way through, I mean the 17, 20 years, that I’ve
been HIV has been exceptionally good in terms of my medical care. And by that
I mean whenever there has been something wrong with me, things have moved
quickly. Whatever treatments were available I had them . . . as the technology
has developed I had access to them. (Neil, London, 52, 1986, HAART)
Neil’s accounts summarizes the sense of shifting technological horizon.
Similarly, Ben refers to the timeliness of HAART in his early experience,
but later a sense of HAART mistimed:
I’ve been lucky I think because if I’d got sick even three years before I did, I
would be dead. When I was in hospital, the main doctor, told [Participant’s
partner] I had two years to live maximum. And then he said ‘Oh actually, make
that one’, because they really did not know how to deal with toxo, they didn’t
know how to manage HIV so well . . . there was a time when I realized I was
running out of options and there was the beginning of discussion and concern
about changing therapy or hitting hard too soon, kind of thing, and I suppose
there was a grain of resentment there somewhere when I thought ‘Well they
could have kept me on it, you know, and now I’m in a position where . . . what
am I going to do if what I’m on currently stops working?’ But I think that’s the
way it had to go, really. I’m quite aware that I am an experiment in progress, but
there’s been good results. (Ben, Glasgow, 40, 1997, HAART)
Ben’s account captures a roller-coaster quality of the post-HAART
experience. Lived experience is embedded in both current and future
technological developments. In the next example, Russell discusses how he
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aimed to avoid a class of anti-HIV drugs because of their reputed side-
effects. He also spoke of delaying the commencement of HAART as a way
of extending time and allowing for technical improvements:
R: I decided when I was doing my research that I wanted to stay away from
protease inhibitors if I could help it in the first instance, and then save them
for later on down the track if I needed another type of drug to fall back on
at some stage.
I: Why did you want to save them for later?
R: The main thing was the side-effects of protease inhibitors and from what I
saw and what I read and talking with other friends who were on treatment
that they were the ones that they felt gave them the worst side-effects and
also impinged on . . . eating an hour beforehand, not drinking for [an] hour
afterwards and all those sort of dietary restrictions which would be – not
impossible, but a bit trickier with me and wanting to continue working full
time. (Russell, London, 33, 1998, HAART)
Russell’s example demonstrates how knowledge about aspects of HAART
is used to develop a treatment strategy that will capitalize on innovation
and further biographical time. In the next example, Stanley discusses a
strategy of taking breaks from treatment to moderate side-effects:
I’m well aware of the risks that are involved . . . to keep on top of those risks I
have myself monitored more often and make sure I know the results and what
have you. And when the time comes we can go back on. But in the meantime
we always try and find a solution to whatever’s caused the problem and I’ve had
to go off them. I was having breaks from therapy long before it was sort of
accepted. It was a definite no-no and other people including friends and other
doctors, apart from my main doctor, were very sceptical and didn’t think it was
a good idea. But as I say I’m very fortunate that Doctor X is brilliant. He really
is. We do work as a team and it’s never been a problem. He always tells me about
stuff I don’t know and it’s never been a problem.
I: So would you say that you work together to come up with solutions?
R: Yes, yes.
I: And you obviously read material and do research outside what . . .
R: I’m not obsessed by it, but if there’s something new coming up I’ll have a
read. I may not necessarily remember it all but at least I’ve had some back-
ground. If something’s wrong with me that I’m not familiar with I’ll go on
the net and find out or read something about it. (Stanley, London, 42, 1985,
HAART)
Stanley’s account makes reference to staying abreast of innovations. Side-
effects are therefore managed by altering treatment, but also in light of
possible future developments. In the next example, Ian discusses lypo-
atrophy of the face and considers a change in treatment:
Well . . . I think I look like Skeletor. My face is quite sunken, but that’s the only
thing that I can see that is different. I mean as I say I’ve always been quite slim.
But now I’m quite gaunt and that that gets me down a bit, to be honest. But
again I’m not that fazed that I change a regime that’s working, just because I
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don’t like the way I look, you know. But, unless they find something to combat
that, I cannot see anyway around that. (Ian, Glasgow, 37, 1992, HAART)
Ian’s account expresses an engagement with technological horizon in
connection with the management of side-effects. His strategy is to keep his
current regime until such time as other options are available. The prospect
of failing treatment required a different kind of approach to uncertainty.
In this context, interviewees turned back to a traditional sense of uncer-
tainty as fate:
I mean what’s that expression: ‘What doesn’t kill you, makes you stronger’ sort
o’ thing. You know so what I’m saying there is that if you don’t have any control
over it, why bother worrying about it? Does that make sense? . . . I don’t know
how I’d feel if they actually turned around and said: ‘Listen all your medication
has failed and you’ve got five minutes to live.’ I think I would (laughs) drop down
at his feet maybe but until that happens I cannot really say . . . I don’t worry
about it. (Ian, Glasgow, 37, 1992, HAART)
In this example, Ian captures a sense of the limits to required agency for
gay men with HIV. For him, recognizing what he is not able to change is a
source of relief. Similarly, Henry also suggests a way of dealing with uncer-
tainty beyond management: ‘Time is the factor on a lot of HIV people. And
if anything, time gives you hope as well, believe it or not . . . I deal with
that bridge when I cross it’ (Henry, Glasgow, 38, 1995, HAART). Henry
relies on a metaphor of a journey to help construct a way of living with
uncertainty. ‘Crossing the bridge’ is a kind of denial of agency, opening the
narrator up to fate, but it is also a source of solace, a way of living with the
uncontrollable.
Discussion
This article has provided a description of experiences of living with
HAART from the points of view of gay men in Glasgow and London.
Instead of a top–down view of how the advent of HAART impacts on
health and well-being, we have aimed to use the accounts of gay men with
HIV to question some of the assumptions of the post-HAART ordering of
knowledge about living with HAART and HIV care.
In general there is a need to guard against globalizing accounts of the
post-HAART situation, common in media and policy and, perhaps, HIV
care. The interviewees expressed tempered hope about HAART, recog-
nizing its benefits and dangers. Unlike previous research, uncertainty itself
did not appear to undermine drug dosing (Lee et al., 2002). Some patients
struggled with the negative aspects of treatment such as intolerance and
side-effects, the emotional impact of uncertainty and the ongoing problems
of social interaction connected with HIV positive serostatus. These are
familiar challenges for people with HIV that can be traced back to the
beginning of the epidemic (Herdt, 2001). Uncertainty, and the social
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challenges of HIV infection in particular, are themes that have not been
erased because of HAART. Instead, the advent and development of
HAART intersects with uncertainty and identity in complex ways.
Our analysis also suggests that diversity among gay men using treatment
characterizes the post-HAART situation. For example, some patients want
to be actively involved in their HIV care, in keeping with the focus on the
relationship or partnership-centred HIV clinical care (Gerbert et al., 2000;
Race, 2001b). Active involvement in treatment is also reflective of the
notion that people affected by HIV have resisted and re-deployed medical
power, for example by increasing access to treatment and user involvement
in clinical research and practice (Epstein, 1996). But the analysis also
suggests that other HAART users prefer a more traditional relationship
with the prescribing clinician, leaving the medical practitioner to make the
best decisions. Such diversity of approaches to HAART suggests that the
resistance of medical power in the post-HAART situation is not universal.
Instead, practices of self-regulation appear more individualized and reflec-
tive of strategic resistance to, and/or co-option of, traditional forms of
medical practice. It may be that as the capacities of HIV medicine develop,
collective resistance becomes less relevant. It is also the case that health
care in general has become more individualizing, reflected in UK policy
frameworks that focus on the expert patient (DOH, 2001). Such individu-
alization and the related reorganization of engagements with medical
power is also in keeping with the notion of ‘precarious freedom’ discussed
by theorists of the late modern social order (Beck and Beck-Gernsheim,
2002; Lash, 2002) or of HIV treatment in particular (Stephenson, 2003). In
addition, as noted by Epstein (2000), patient involvement in HIV clinical
practice and research can become reflective of social divisions to do with
class and ethnicity. Our analysis suggests nuanced engagements with
medical power, reflecting technological innovations and changes in health
care subjectivity, structured by social differences such as educational back-
ground and ethnicity.
This article focused on the different modes of accounting for life with
HAART (before treatment; good health; post-illness; loss of confidence)
as a way of exploring the interplay of use of HAART, uncertainty and
expectations. The analysis raised questions for further research, HIV care
and HIV prevention.
There is a need for more information about individual therapeutic
responses to HAART. Our current picture of the effectiveness of HAART
is limited to global mortality statistics and clinical trials data (http://www.
bhiva.org/guidelines/2005/HIV/HIV05frameset.html, 1 December 2005).
Such data suggest that the ‘good health’ mode of experience may be the
most prevalent. But as our research suggests, global statistics tell part of
the story and may mask marginal experiences with HAART. In particular,
we know little about the extent of the other ‘post-illness’ and ‘loss of confi-
dence’ modes of the HAART experience and their place in clinical practice.
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These modes may well be statistically small, generational and indeed
reducing as HAART improves. But we need to be more confident that this
is the case.
The different modes of the HAART experience discussed in this article
suggest the specific psychosocial support needs of different people with
HIV. The ‘post-illness’ and ‘loss of confidence’ groups may need kinds of
support very different to the needs of those without serious illness or side-
effects. Other researchers have suggested high levels of psychiatric morbid-
ity among gay men with HIV using HAART (McNaught and Spicer, 2000).
The fragility and loss of confidence expressed by some of the interviewees
indicate emotional distress. The situation may be especially difficult for such
patients as they comprise small groups and therefore may not be the main
focus for HIV care. In addition, the interviews provide the basis for an
approach to psychosocial care grounded in the methods and strategies used
by gay men with HIV themselves. Recent work on self-care has adopted a
deficit model and thereby has identified a role for psychosocial interven-
tions such as cognitive behaviour modification (Kalichman et al., 1998).
Some gay men may profit from such interventions. But we argue that inter-
ventions may be improved by understanding the different ways that people
with HIV approach uncertainty.
The prevention needs of gay men with HIV may also vary depending on
how they engage with HAART and their preferences for managing uncer-
tainty. For example, the HIV prevention concerns of HIV positive gay men
not using HAART or in good health, may be different to those patients
who have had serious illness and side-effects. As with psychosocial care,
practitioners need to be sensitized to the HIV prevention needs of differ-
ent gay men with HIV. A key concept in HIV prevention research has been
the idea of treatment optimism, derived from the health belief model, and
its association with self-reported anal sex without condoms (International
Collaboration on HIV Optimism, 2003). The accounts described in this
article suggest that the notion of treatment optimism may be somewhat
simplistic. HIV prevention researchers need to engage with the idea that
gay men with HIV are not all the same in terms of how they engage with
HAART and their experiences with it.
A key contribution of this article is the account of how people living with
HAART use the idea of technological horizon to frame their engagements
with uncertainty. Alongside the generalized idea of hope, and the necess-
ary daily drug dosing and treatment monitoring, through the idea of techno-
logical horizon there is also scope for an active engagement with the
uncertainties of the post-HAART situation. Patients spoke of delaying
HAART, managing change and maximizing the benefit of technical
advances. These strategies mirror how prescribing clinicians manage
HAART on an individual basis. Current clinical guidance uses categories
that resemble the accounts discussed in this study, including: when to treat;
and when to change treatment (http://www.bhiva.org/guidelines/2005/HIV/
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HIV05frameset.html, 1 December 2005). Research has come to focus on
the doctor/patient relationship in HIV treatment as a focus for interven-
tion (Gerbert et al., 2004) and as an innovation of medico-social relations
specific to the uncertainties of the post-HAART situation (Race, 2001b).
We suggest that the idea of technological horizon is the organizing discourse
of the HIV treatment partnership. We suggest then that different forms of
engagement with prescribing can be framed by this idea of technological
horizon because it provides a way for both patients and clinicians to manage
post-HAART uncertainties.
A kind of post-HAART fatalism also emerged as a way of defining the
limits of personal responsibility. Fatalism is often characterized as a failure
of the reflexive self, as a kind of giving up. In contrast, we argue that fate
has value for patients because it provides a freedom to exist without blame.
Chronic illness self-management discourse is often critiqued because it
mobilizes moral judgement of those who are seen to fail to act to care for
themselves in a responsible manner (Galvin, 2002). In this discourse,
fatalism is regarded as a kind of denial or failure of reflexivity. We agree
that chronic illness discourse is overly blaming, particularly as it seems to
us that refusing reflexivity may also be an act of freedom. People with HIV
need to be free to settle on fatalism as a way of existing with the limits of
technological innovation in the treatment of HIV.
Note
1. Personal communication with Dr Jane Anderson, Barts and the London
Hospitals Trust (2004). Dr Anderson suggested that the term ‘post-HAART’
was used in clinical practice.
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